{
    "clinical_study": {
        "@rank": "72246", 
        "arm_group": [
            {
                "arm_group_label": "Type 2 DM", 
                "arm_group_type": "Active Comparator", 
                "description": "Intervention : Oral fat tolerance test\nwell or moderately controlled type 2 diabetes mellitus (HbA1c < 10%) No dipeptidyl peptidase-4 -inhibitor, Glucagon-like peptide-1 agonist, thiazolidinediones"
            }, 
            {
                "arm_group_label": "Prediabetes", 
                "arm_group_type": "Active Comparator", 
                "description": "Intervention : Oral fat tolerance test\nGlucose 140-199 mg/dL after 75g oral glucose tolerance test HbA1c 5.7-6.4%"
            }, 
            {
                "arm_group_label": "Normal glucose tolerance", 
                "arm_group_type": "Sham Comparator", 
                "description": "Intervention : Oral fat tolerance test\nNo impaired fasting glucose and impaired glucose tolerance"
            }
        ], 
        "brief_summary": {
            "textblock": "The hypertriglyceridemia at fasting status has been known to be an important risk factor for\n      cardiovascular disease (CVD). Recently, postprandial triglyceride (TG) levels draw an\n      attention as a superior predictor of CVD because of non-fasting state for more than 12 hours\n      and importance of triglyceride-rich lipoprotein.\n\n      We aim to investigate the relationship of postprandial triglyceride after fat tolerance test\n      and intima-medial thickness and to suggest normal reference of postprandial triglyceride\n      after fat tolerance test. In addition, we evaluate the correlation of postprandial\n      triglyceride and incretin secretion after fat tolerance test Ultimately, we want to estimate\n      clinical importance of postprandial triglyceride in assessment of cardiovascular risk."
        }, 
        "brief_title": "The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Prediabetes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Glucose Intolerance", 
                "Prediabetic State"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age : 19 ~ 70 yrs\n\n          -  Type 2 diabetes : HbA1c <10%\n\n          -  Prediabetic state : HbA1c 5.7~6.4%\n\n        Exclusion Criteria:\n\n          -  Type 1 diabetes, secondary diabetes\n\n          -  dipeptidyl peptidase-4 -inhibitor, glucagon-like peptide-1 agonist,\n             thiazolidinediones users\n\n          -  Thyroid disease with abnormal thyroid function test\n\n          -  Liver disease with abnormal liver function test\n\n          -  severe kidney disease\n\n          -  pregnant or lactating women\n\n          -  current smoker\n\n          -  severe obesity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01972542", 
            "org_study_id": "SNUBH-ENDO4"
        }, 
        "intervention": {
            "arm_group_label": [
                "Type 2 DM", 
                "Prediabetes", 
                "Normal glucose tolerance"
            ], 
            "intervention_name": "Oral fat tolerance test", 
            "intervention_type": "Dietary Supplement"
        }, 
        "intervention_browse": {
            "mesh_term": "Dipeptidyl-Peptidase IV Inhibitors"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Postprandial period", 
            "triglyceride", 
            "Diabetes mellitus, type 2", 
            "Prediabetic state"
        ], 
        "lastchanged_date": "October 24, 2013", 
        "location": {
            "contact": {
                "email": "limsoo@snu.ac.kr", 
                "last_name": "Soo Lim, MD, MPH, PhD", 
                "phone": "+82-31-787-7035"
            }, 
            "facility": {
                "address": {
                    "city": "Seongnam", 
                    "country": "Korea, Republic of", 
                    "zip": "463-707"
                }, 
                "name": "Seoul National University Bundang Hospital"
            }, 
            "investigator": {
                "last_name": "Soo Lim, MD, MPH, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk in Healthy People, Impaired Glucose Tolerance and Type 2 Diabetes", 
        "overall_contact": {
            "email": "limsoo@snu.ac.kr", 
            "last_name": "Soo Lim, MD, MPH, PhD", 
            "phone": "+82-31-787-7035"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Bundang Hospital", 
            "last_name": "Soo Lim, MD, MPH, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood sample : drawn by a catheter before the meal and every 1 hour after meal over the 8-hour period", 
            "measure": "Changes of Triglyceride", 
            "safety_issue": "No", 
            "time_frame": "8 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01972542"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Bundang Hospital", 
            "investigator_full_name": "Soo Lim", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Changes of incretin", 
            "safety_issue": "No", 
            "time_frame": "8 hours"
        }, 
        "source": "Seoul National University Bundang Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Bundang Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}